SCHEMBL25918978

SCHEMBL25918978

CCc1cnn(C2CCCCO2)c1C(C)C

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 1/20 0.42
▸ LMNA P02545 1/20 0.42
▸ POLB P06746 1/20 0.42
▸ CYP4F2 P78329 4/20 0.39
▸ CYP4A11 Q02928 4/20 0.39
▸ KDM5B Q9UGL1 1/20 0.39
▸ RXRA P19793 1/20 0.38
▸ RXRB P28702 1/20 0.38
▸ RXRG P48443 1/20 0.38
▸ RET P07949 5/20 0.34
▸ ATR Q13535 1/20 0.33
▸ MEN1 O00255 1/20 0.33
▸ KMT2A Q03164 1/20 0.33
▸ PDE1A P54750 1/20 0.33
▸ PDE1B Q01064 1/20 0.33
▸ PDE1C Q14123 1/20 0.33
▸ GAA P10253 1/20 0.33
▸ YTHDC1 Q96MU7 1/20 0.32
▸ CNR2 P34972 1/20 0.32
▸ CYP2C19 P33261 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21185054 0.83 CYP4F2 (0.45) ALDH1A1LMNAPOLBCYP4F2CYP4A11
SCHEMBL26964613 0.82 CYP4F2 (0.44) ALDH1A1LMNAPOLBCYP4F2CYP4A11
SCHEMBL26964696 0.82 ALDH1A1 (0.43) ALDH1A1LMNAPOLBCYP4F2CYP4A11
SCHEMBL24702054 0.80 ALDH1A1 (0.41) ALDH1A1LMNAPOLBCYP4F2CYP4A11
SCHEMBL26964763 0.80 ALDH1A1 (0.41) ALDH1A1LMNAPOLBCYP4F2CYP4A11
SCHEMBL25342107 0.75 ALDH1A1 (0.40) ALDH1A1LMNAPOLBCYP4F2CYP4A11
SCHEMBL13444764 0.74 CYP4F2 (0.45) ALDH1A1LMNAPOLBCYP4F2CYP4A11
SCHEMBL24638319 0.74 ALDH1A1 (0.41) ALDH1A1LMNAPOLBCYP4F2CYP4A11
SCHEMBL24177147 0.74 ALDH1A1 (0.39) ALDH1A1LMNAPOLBCYP4F2CYP4A11
SCHEMBL18418891 0.73 ALDH1A1 (0.49) ALDH1A1LMNAPOLBCYP4F2CYP4A11

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230226074-A1 METHODS OF USE FOR PYRIMIDINES AS FERROPORTIN INHIBITORS GLOBAL BLOOD THERAPEUTICS INC (US) 2023-07-20 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230226074-A1 METHODS OF USE FOR PYRIMIDINES AS FERROPORTIN INHIBITORS SLC40A1, HAMP, SLC19A1 ALDH1A1 918/4885LMNA 1425/4885POLB 355/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback